Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02619812 · ClinicalTrials.gov registry record · Phase 2
Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02619812: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT02619812 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02619812, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
For patients who receive a hematopoietic cell transplant (HCT), there is a risk of developing a diarrhea secondary to the chemotherapy which we give. Diarrhea is usually harmless in healthy adults; however, in transplant patients, diarrhea can result in dehydration, negative impact on quality of life, and prolonged hospitalization. The purpose of this study was to see if Colesevelam (Welchol) and Serum-derived bovine immunoglobulin-protein (SBI) result in a change in the frequency or consistency of your bowel movements.
Interventions
- DRUG Colesevelam
- OTHER Serum-derived bovine immunoglobulin/protein isolate (SBI)
- OTHER Double Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02619812
The ClinicalTrials.gov registry entry for NCT02619812 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Colesevelam is the first listed.
NCT02619812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02619812 about?
NCT02619812 is a clinical study titled "Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT". For patients who receive a hematopoietic cell transplant (HCT), there is a risk of developing a diarrhea secondary to the chemotherapy which we give. Diarrhea is usually harmless in healthy adults; however, in transplant patients, diarrhea can result in dehydration, negative impact on quality of lif...
What is the current status of trial NCT02619812?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2016-04. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02619812?
The interventions under investigation include: Colesevelam (DRUG), Serum-derived bovine immunoglobulin/protein isolate (SBI) (OTHER), Double Placebo (OTHER).
Who is sponsoring clinical trial NCT02619812?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.